Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 7/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21600577 | 0.87 | HTR1A (0.43) | HTR1AMPOSLC6A4GPR84 | |
| SCHEMBL5389368 | 0.81 | HTR2A (0.36) | HTR1AGPR84HTR2CHTR2ACYP2D6 | |
| SCHEMBL5398443 | 0.77 | HTR1A (0.42) | HTR1AMPOSLC6A4GPR84HTR2C | |
| SCHEMBL1164344 | 0.77 | HTR1A (0.48) | HTR1AMPOSLC6A4GPR84HTR2A | |
| SCHEMBL5392766 | 0.76 | HTR1A (0.38) | HTR1AMPOSLC6A4GPR84 | |
| SCHEMBL25885809 | 0.71 | HTR1A (0.62) | HTR1AMPOSLC6A4GPR84HTR2C | |
| SCHEMBL19216724 | 0.70 | HTR1A (0.36) | HTR1AGPR84 | |
| SCHEMBL20576934 | 0.70 | ALDH1A1 (0.35) | HTR1AGPR84 | |
| SCHEMBL31730633 | 0.70 | HTR2A (0.59) | HTR1AMPOSLC6A4GPR84HTR2C | |
| SCHEMBL2537704 | 0.70 | HTR2A (0.59) | HTR1AMPOSLC6A4GPR84HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217730-B2 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | WYETH (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1509225-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | Wyeth (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | WYETH (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2003099275-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | HAVCR2, HCCS, ZC3HAV1 | HTR1A 347/4885MPO 1741/4885SLC6A4 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.